- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03474263
IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)
A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, biomarkers-driven study.
Patients with rapidly progressive ALS will be assigned to the following dose regimen of IC14:
• 4 mg/kg intravenously on Day 1, followed by 2 mg/kg daily x 3 days on Days 2-4. This 4-day course will be repeated on Days 8-11.
Patients will be followed for 28 days after the last dose of study drug. Patients will all undergo [11C]-PBR28-MR-PET scans at two time points: before treatment onset and after the last treatment cycle.
Patients will be followed for 28 days after the last dose of study drug for safety.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Queensland
-
Herston, Queensland, Australia, 4006
- Royal Brisbane & Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Capable of providing informed consent and informed consent form signed prior to initiation of any study-specific procedures.
- Familial or sporadic ALS defined as clinically possible, probable, or definite by El Escorial Criteria.
- Rapidly progressive ALS defined by the Revised ALS Functional Rating Scale (ALSFRS-R) slope ≥1 (48 minus ALSFRS-R score at screening / disease duration in months ≥ 1).
- Upper Motor Neuron Burden Score of ≥ 25 (out of 45) at screening
- First symptoms of ALS within 3 years of the screening visit
- Age between 18 and 80 years at the time of the screening visit.
- Not taking riluzole or edaravone or on a stable dose of riluzole or edaravone for at least 3 months prior to screening visit.
Adequate bone marrow reserve, renal and liver function:
- absolute neutrophil count ≥ 1500/µL
- lymphocyte count < 6000/µL
- platelet count ≥ 150,000/µL
- hemoglobin ≥ 11 g/dL
- creatinine clearance ≥ 60 mL/min
- alanine transaminase (ALT) and/or aspartate transaminase (AST) ≤ 3x upper limits of normal (ULN)
- total bilirubin ≤ 1.5x ULN
- serum albumin ≥ 2.8 g/dL
Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods:
- Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or
- Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or
- Stable hormonal contraception for at least 3 months prior to study through study completion; or
- Surgical sterilization (vasectomy) of male partner at least 6 months prior to study.
- To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses.
- Males with female partners of childbearing potential must use contraception through study completion.
- Ability to safely lie flat for 90 min for magnetic resonance-positron emission tomography (MR-PET) procedures in the opinion of the Investigator.
- Patients must also have a genotype associated with a high or mixed affinity translocator protein (TSPO) (Ala/Ala or Ala/Thr) and ability to safely undergo MR-PET scans based on the opinion of the Investigator.
Exclusion Criteria:
- Dependence on invasive or non-invasive ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at screening; or presence of diaphragm pacing system at screening.
- Exposure to any experimental treatment for ALS within the last 30 days or five half-lives, whichever is longer.
- Treatment within 12 months with immunomodulator or immunosuppressant agent (including but not limited to cyclophosphamide, cyclosporine, interferon-α, interferon-β-1a, rituximab, alemtuzumab, azathioprine, etanercept, infliximab, adalimumab, certolizumab, golimumab, anakinra, rilonacept, secukinumab, tocilizumab, mycophenolate mofetil, methotrexate, cell-depleting agents, total lymphoid irradiation, dimethyl fumarate). Treatment with intravenous immunoglobulin (IVIG) within 2 months. Non-steroidal anti-inflammatory drugs (NSAIDs) are acceptable.
- Exposure at any time to any cell or gene therapies under investigation for the treatment of ALS.
- Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections; or major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks.
- Live-attenuated vaccines within 30 days before dosing. Subjects must agree to forego live-attenuated vaccines throughout the study, including 60 days after the last dose of study drug.
- History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.
- History of one or more of the following: cardiac insufficiency (New York Heart Association [NYHA] III/IV), uncontrolled cardiac arrhythmias, unstable ischemic heart disease, or uncontrolled hypertension (systolic blood pressure > 170 mmHg or diastolic blood pressure > 110 mmHg).
- History of myocardial infarction, or cerebrovascular accident.
- Unstable pulmonary, renal, hepatic, endocrine or hematologic disease.
- Autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis.
- Evidence of active malignant disease, malignancies diagnosed within the previous 5 years, or breast cancer diagnosed within the previous 5 years (except skin cancers other than melanoma).
- History of human immunodeficiency virus infection or other immunodeficiency illness.
- Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days.
- History of drug abuse (not including marijuana use) or alcoholism within the past 12 months.
- Significant neuromuscular disease other than ALS.
- Other ongoing disease that may cause neuropathy, such as toxin exposure, dietary deficiency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupus erythematosus or other connective diseases, infection with HIV, hepatitis B virus (HBV), or hepatitis C (HCV), Lyme disease, multiple myeloma, Waldenström's macroglobulinemia, amyloid, and hereditary neuropathy.
- Pregnancy or breastfeeding.
- Deprivation of freedom by administrative or court order.
- Any contraindication to undergo magnetic resonance imaging (MRI) studies such as history of a cardiac pacemaker or pacemaker wires; metallic particles in the body; vascular clips in the head; prosthetic heart valves; or severe claustrophobia.
- Unwilling or unable to discontinue benzodiazepine usage [other than lorazepam (Ativan®), clonazepam (Klonopin®), or zolpidem (Ambien®)] for one day prior to and during scanning.
- Research imaging-related radiation exposure exceeds current institutional Radiology Department guidelines
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IC14 (monoclonal anti-CD14 antibody)
Biologic: IC14 (monoclonal anti-CD14 antibody) 4 mg/kg intravenously followed by IC14 2 mg/kg intravenously on Days 2-4.
This four-day cycle will be repeated on Days 8-11.
|
IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glial Activation
Time Frame: one month
|
Glial activation measured in the motor region measured by [11C]-PBR28 positron emission tomography (PET).
Studies have shown this marker localizes to areas of glial activation and correlates with disease progression and outcomes.
|
one month
|
Serum neurofilament
Time Frame: one month
|
Serum neurofilament is a biomarker that has been shown to correlate with ALS severity
|
one month
|
Urinary p75 neurotrophin receptor
Time Frame: one month
|
Urinary p75 neurotrophin receptor is a biomarker that has been shown to correlate with ALS severity
|
one month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events (Safety, Tolerability)
Time Frame: six weeks
|
Adverse event reporting
|
six weeks
|
Immunogenicity
Time Frame: six weeks
|
Human anti-monoclonal antibodies
|
six weeks
|
Peak Plasma Concentration of IC14
Time Frame: one month
|
Peak Plasma Concentration (Cmax) of IC14
|
one month
|
Pharmacodynamics
Time Frame: one month
|
Monocyte CD14 saturation
|
one month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jan Agosti, MD, Implicit Bioscience Ltd.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Sclerosis
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Antibodies, Monoclonal
Other Study ID Numbers
- ALS02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on Biologic: IC14 (monoclonal antibody against human CD14)
-
Implicit BioscienceRoyal Brisbane and Women's HospitalCompletedMotor Neuron Disease | Amyotrophic Lateral SclerosisAustralia
-
Implicit BioscienceWithdrawnAcute Respiratory Distress Syndrome
-
Implicit BioscienceNo longer availableCOVID | SARS-CoV2 | ARDS, Human | ArdsItaly
-
National Institute of Allergy and Infectious Diseases...PPD; University of Washington; Vanderbilt University Medical Center; Implicit BioscienceTerminatedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Disease 2019 (COVID-19)United States
-
Bio-Thera SolutionsActive, not recruitingPlaque PsoriasisChina
-
AbbVie (prior sponsor, Abbott)CompletedMultiple SclerosisUnited States, Canada, Germany, Netherlands, United Kingdom
-
Probiomed S.A. de C.V.UnknownDiffuse Large B Cell LymphomaMexico
-
BiocadCompleted